{"doi":"10.1016/j.ijid.2024.107265","title":"Impact of early antiviral therapy on SARS-CoV-2 clearance time in high-risk COVID-19 subjects: A propensity score matching study","abstract":null,"journal":"International Journal of Infectious Diseases","year":2024,"id":630341,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1632923,"name":"Federico Fama","orcid":"0009-0002-1423-7415","position":1,"is_corresponding":false},{"id":1632924,"name":"Federico Fassio","orcid":"0000-0002-7252-4917","position":2,"is_corresponding":false},{"id":1632926,"name":"Darcy Holmes","orcid":null,"position":3,"is_corresponding":false},{"id":1632927,"name":"Giovanni Scaglione","orcid":null,"position":4,"is_corresponding":false},{"id":1632928,"name":"Chiara Mariani","orcid":null,"position":5,"is_corresponding":false},{"id":1632929,"name":"Lucia Galli","orcid":null,"position":6,"is_corresponding":false},{"id":1056425,"name":"Alessia Lai","orcid":"0000-0002-3174-5721","position":7,"is_corresponding":false},{"id":1056423,"name":"Spinello Antinori","orcid":"0000-0003-0569-9407","position":8,"is_corresponding":false},{"id":614563,"name":"Andrea Gori","orcid":"0000-0001-6587-4794","position":9,"is_corresponding":false},{"id":218069,"name":"Agostino Riva","orcid":"0000-0003-3171-3049","position":10,"is_corresponding":false},{"id":1632933,"name":"Monica Schiavini","orcid":null,"position":11,"is_corresponding":false},{"id":1632922,"name":"Marta Colaneri","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Impact of early antiviral therapy on SARS-CoV-2 clearance time in high-risk COVID-19 subjects: A propensity score matching study","abstract":"BACKGROUND: Effective treatments for COVID-19 are needed to mitigate disease progression and reduce the burden on healthcare systems. This study investigates the impact of early treatments on SARS-CoV-2 viral shedding duration among high-risk individuals with mild symptoms. METHODS: A single-center, retrospective observational study was conducted at Luigi Sacco Hospital in Milan from December 2021 to March 2023. Hospitalized and nonhospitalized adults with a confirmed SARS-CoV-2 infection and at high-risk of disease progression were enrolled. Unadjusted and adjusted negative binomial regression models and a Random Forest regression model were performed before and after matching subjects based on their propensity of being treated or not. RESULTS: Results from 518 subjects (428 treated and 90 untreated) revealed a significant reduction in SARS-CoV-2 viral shedding duration among those who received early treatment compared to untreated individuals. Propensity score matching and multivariable regression analyses confirmed this finding. Early treatment significantly reduced the risk of COVID-19-related hospitalization and pneumonia development. Subgroup analysis identified COPD as a potential factor influencing effectiveness of early treatments. CONCLUSIONS: Early treatments play a crucial role in reducing SARS-CoV-2 viral shedding and preventing disease progression among high-risk individuals. Shorter viral shedding duration also contributes to improved healthcare resource utilization and infection control measures.","is_dataset_classified":null,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39393523","pmcid":null,"openalex_id":"https://openalex.org/W4403303722","authors":[],"funders":[{"funder_name":"European Commission","grant_id":"101046314","title":"ENDING COVID 19 VARIANTS OF CONCERN THROUGH COHORT STUDIES: END-VOC"},{"funder_name":"European Commission","grant_id":"2020/ST/049","title":null}],"total_grants":2,"fwci":1.8341,"citation_percentile":0.85694764,"influential_citations":0,"citation_trend":[{"year":2025,"count":1},{"year":2026,"count":5}],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://www.ijidonline.com/article/S1201-9712(24)00336-9/pdf","host_type":"journal"},{"url":"https://www.ijidonline.com/article/S1201-9712(24)00336-9/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1201971224003369?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1201971224003369?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ijid.2024.107265","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39393523","host_type":"repository"},{"url":"https://doaj.org/article/6740203e726242589fb1d53b909529e8","host_type":"repository"},{"url":"https://hdl.handle.net/2434/1111968","host_type":""},{"url":"http://dx.doi.org/10.1016/J.IJID.2024.107265","host_type":""},{"url":"http://dx.doi.org/10.1016/j.ijid.2024.107265","host_type":""}],"fields_of_study":["COVID-19 Clinical Research Studies","SARS-CoV-2 and COVID-19 Research","Long-Term Effects of COVID-19","0301 basic medicine","03 medical and health sciences","0302 clinical medicine"],"mesh_terms":["COVID-19","SARS-CoV-2","COVID-19 Drug Treatment","Adult","Aged","Antiviral Agents","Female","Hospitalization","Humans","Male","Middle Aged","Retrospective Studies","Virus Shedding","Disease Progression","Propensity Score"],"keywords":["Coronavirus disease 2019 (COVID-19)","Propensity score matching","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","2019-20 coronavirus outbreak","Medicine","Matching (statistics)","Virology","Internal medicine","Disease","Infectious disease (medical specialty)","Pathology","Outbreak","COPD","High-risk Subjects","Viral Shedding","Covid-19","Early Treatments","Time To Negativization","Male","Adult","Infectious and parasitic diseases","RC109-216","Antiviral Agents","COPD; COVID-19; early treatments; high-risk subjects; time to negativization; viral shedding","Humans","Propensity Score","Retrospective Studies","Aged","SARS-CoV-2","Middle Aged","Virus Shedding","COVID-19 Drug Treatment","Hospitalization","Disease Progression","Female"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T21:01:06.832678Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}